China’s Inner Mongolia Autonomous Region Food and Drug Administration recently issued a notice on 25 batches of drugs that did not meet the requirements, indicating that in 1 batch of Qianhu (drugs) produced by Anhui Xiehecheng Pharmaceutical Decoction Pieces Co., Ltd. (also known as Anhui Xiehecheng Chinese Herb Limited) (Lot number: 19041903), the content determination items were found to be inconsistent with the regulations in China.
It is understood that the content determination item refers to the determination of the content of active ingredients in raw materials and preparations by prescribed test methods, and generally chemical, instrumental, or biological determination methods can be used. The content determination is related to the efficacy of the drug.
Xiehecheng Pharmaceutical Company has been exposed several times before that its Chinese medicines are not qualified.
The Fujian Drug Quality Notice (Phase 1 of 2021) issued by the Fujian Drug Administration on April 12, 2021 shows that a batch of white lentils (production batch number: 18092612) produced by Xiehecheng Pharmaceutical Co., Ltd. has been found not meeting the requirements. It is reported that according to the materials provided by the supervisory department where the production company is located, the non-compliance of the properties of the batch of drugs is caused by the manufacturer’s requirements for mashing.
In September 2020, the Fujian Drug Quality Announcement (No. 2 of 2020) issued by the Fujian Provincial Food and Drug Administration showed that a batch of rice sprouts (drug batch number: 18062901) produced by Xiehecheng Pharmaceutical Co., Ltd. was detected that an inspection item was not qualified. However, the company denied that it had produced this batch of drugs.
The Zhejiang Provincial Food and Drug Administration issued the 5th Zhejiang Drug Quality Announcement of 2019 in October 2019, showing that a batch of white lentils (batch number: 1.6121417E7) produced by Xiehecheng Pharmaceutical Co., Ltd. was found to be out of compliance with the requirements in China.
In addition, Tianyancha.com data shows that Xiehecheng Pharmaceutical Co., Ltd. has nearly 80 administrative penalties (from 2015 to 2020), involving the production and sales of drugs that do not meet the requirements; production and sales of inferior drugs; production of drugs without a “drug production license”, etc.
According to the information on the official website of Xiehecheng Pharmaceutical Company, the company is a modern Chinese medicine enterprise integrating medicinal materials planting, Chinese medicine decoction pieces processing, Chinese patent medicine manufacturing, product research and development, import and export trade, with a registered capital of 66.6 million yuan and total assets of more than 800 million yuan. It has won the Famous Brand of Anhui Province, Anhui Province Quality Award, Anhui Province Pharmaceutical Quality Management Award, Bozhou Government Quality Award and other honorary titles.
Its main products include Chinese medicine decoction pieces, Chinese patent medicine preparations, and Chinese medicine extracts, it especially has unique processing technology and production capacity for exporting refined beverage tablets. Anhui Xiehecheng Chinese Herb Limited has four wholly-owned subsidiaries, involving Anhui Bencao Chinese Medicine Herb Pieces Co. Ltd., Bozhou Traditional Chinese Medicine Import and Export Testing Center, Anhui Xiehecheng Pharmaceutical Co., Ltd., and Anhui Xiehecheng Pawn Co., Ltd.
Source: China Quality News